Title:Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
Volume: 16
Issue: 5
Author(s): Antonio González-Martín, Emilio Alba, Eva Ciruelos, Javier Cortés, Antonio Llombart, Ana Lluch, Raquel Andrés, Isabel Álvarez, José Manuel Aramendía, Francisco Ayala de la Peña, Agustí Barnadas, Norberto Batista, Lourdes Calvo, Elena Galve, Andrés García-Palomo, José Ángel García-Sáenz, Juan de la Haba, Rafael López, Guillermo López-Vivanco, Noelia Martínez-Jáñez, Eduardo Martínez de Dueñas, Arrate Plazaola, Álvaro Rodríguez-Lescure, Manuel Ruiz, Pedro Sánchez-Rovira and Ana Santaballa, Miguel Ángel Seguí, Ignasi Tusquets, Pilar Zamora, Miguel Martín
Affiliation:
关键词:
卡培他滨，化疗，多烯紫杉醇，转移性乳腺癌，白蛋白结合型紫杉醇，紫杉醇。
摘要: Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is
recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all
patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound
(nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be
administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel
may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line
treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane
and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard
taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with
prior exposure to a standard taxane.
